中國醫療集團(08225.HK)擬與加拿大公司開展國際生物等效性試驗
中國醫療集團(08225.HK)公布,關聯製造企業於今年2月25日獲得抗病毒產品邁可欣(利托那韋口服液)國藥准字生產註冊批准後,收到多國採購需求,集團擬與一家加拿大公司開展國際生物等效性試驗和國際註冊。此外,集團正與高濟醫療、海王星辰、微醫集團、妙手醫療等建立研究數字型專區藥診,聚焦危機心理專區,拜敏抗敏專區,戒煙長命專區。致力於疫情後時代疫情心理與過敏治療。危機心理疾病致殘死亡將超越新冠病毒肺炎本身。吸煙患者死亡率也遠高於非吸煙患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.